Loxo Oncology, Inc. (LOXO) Financial Statements (2023 and Earlier)

Company Profile

Business Address 281 TRESSER BOULEVARD, 9TH FLOOR
STAMFORD, CT 06901
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:626,200141,800153,892106,292
Cash and cash equivalents142,02530,37668,17743,930
Short-term investments484,175108,93585,71562,362
Other undisclosed cash, cash equivalents, and short-term investments 2,489  
Other undisclosed current assets155,607(6)2,7521,484
Total current assets:781,807141,794156,644107,776
Noncurrent Assets
Property, plant and equipment9122488812
Long-term investments and receivables 2,499 6,648
Long-term investments 2,499 6,648
Deposits noncurrent assets   23
Other noncurrent assets723771726 
Total noncurrent assets:1,6353,5188146,683
TOTAL ASSETS:783,442145,312157,458114,459
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities26,53315,1442,8531,787
Accounts payable3,9961,061269239
Accrued liabilities22,53714,0832,5841,548
Deferred revenue and credits195,037   
Total current liabilities:221,57015,1442,8531,787
Noncurrent Liabilities
Liabilities, other than long-term debt183,662   
Deferred revenue and credits183,662   
Total noncurrent liabilities:183,662   
Total liabilities:405,23215,1442,8531,787
Stockholders' equity
Stockholders' equity attributable to parent378,210130,168154,605112,672
Common stock3222
Additional paid in capital666,891269,423221,457143,660
Accumulated other comprehensive loss(572)(21)(16)(28)
Accumulated deficit(288,112)(139,236)(66,838)(30,962)
Total stockholders' equity:378,210130,168154,605112,672
TOTAL LIABILITIES AND EQUITY:783,442145,312157,458114,459

Income Statement (P&L) ($ in thousands)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues
(Revenue, Net)
 56  
Gross profit: 56  
Operating expenses(173,696)(73,178)(24,464)(13,122)
Other undisclosed operating income (loss)21,300(56) (7,568)
Operating loss:(152,396)(73,178)(24,464)(20,690)
Loss from continuing operations before equity method investments, income taxes:(152,396)(73,178)(24,464)(20,690)
Other undisclosed income (loss) from continuing operations before income taxes 778(11,611)41,390
Income (loss) before gain (loss) on sale of properties:(152,396)(72,400)(36,075)20,700
Other undisclosed net income3,520   
Net income (loss):(148,876)(72,400)(36,075)20,700
Other undisclosed net income (loss) attributable to parent 2199(41,372)
Net loss attributable to parent:(148,876)(72,398)(35,876)(20,672)
Preferred stock dividends and other adjustments   (34)
Net loss available to common stockholders, diluted:(148,876)(72,398)(35,876)(20,706)

Comprehensive Income ($ in thousands)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(148,876)(72,400)(36,075)20,700
Comprehensive income (loss):(148,876)(72,400)(36,075)20,700
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(551)(3)211(41,400)
Comprehensive loss, net of tax, attributable to parent:(149,427)(72,403)(35,864)(20,700)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: